X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• X4 Pharmaceuticals Inc XFOR.OQ reported a quarterly adjusted loss of $3.47​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-2.10. The mean expectation of five analysts for the quarter was for a loss of $4.34 per share. Wall Street expected results to range from $-5.57 to $-3.57 per share.

• Revenue rose 250.4% to $1.97 million from a year ago; analysts expected $1.61 million.

• X4 Pharmaceuticals Inc's reported EPS for the quarter was a loss of $3.47​.

• X4 Pharmaceuticals Inc shares had fallen by 23.2% this quarter and lost 93.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for X4 Pharmaceuticals Inc is $14.00, about 89.6% above its last closing price of $1.46

This summary was machine generated from LSEG data August 8 at 09:40 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)